Ginkgo biloba

EMA Well-Established Use extract (EGb 761) for age-related cognitive complaints; Cochrane evidence in dementia is inconsistent and NICE advises against herbal products for dementia.

Evidence
Preliminary evidenceGRADE certainty: Low
Typical dose
EGb 761 standardised extract 120–240 mg/day, in one or two divided doses
Time to effect
Cognitive endpoints typically assessed over 12–24 weeks
Safety
Has documented cautions

Evidence ratings summarise published research on Ginkgo biloba in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.

Ask about Ginkgo biloba

Interactions

Taking any medication?

Check Ginkgo biloba against it.

Why

Ginkgo biloba leaf extract (EGb 761) holds an EMA Well-Established Use monograph for age-related cognitive complaints. The Cochrane review of ginkgo for cognitive impairment and dementia found inconsistent results, with three of the four most recent trials showing no difference from placebo. A separate Cochrane review found no clinically significant walking-distance benefit in intermittent claudication. NICE advises against herbal products for dementia.

How it works

Terpene lactones (ginkgolides A, B, C and bilobalide) inhibit platelet-activating factor and are proposed to improve microvascular perfusion. Flavonoid glycosides act as antioxidants in laboratory studies.

Expected onset · Cognitive endpoints typically assessed over 12–24 weeks

How to take

Dosage

EGb 761 standardised extract 120–240 mg/day, in one or two divided doses.

Timing

Morning, or split morning + evening

On the label

Look for 'EGb 761' or extracts standardised to 24% flavone glycosides and 6% terpene lactones. Unstandardised leaf preparations are poorly characterised.

Studied in

Older adults with subjective memory complaints or age-related cognitive complaints who want to discuss the EMA-listed extract with a doctor.

Safety

Anti-platelet effect; usually stopped at least 2 weeks before surgery. Caution with warfarin, DOACs, antiplatelets, SSRIs, and NSAIDs. Avoid in pregnancy. Seizure threshold concerns at very high doses; avoid in epilepsy.
Loading interactions…

Evidence

At a glance

Birks & Grimley Evans 2009 Cochrane Database Syst Rev (36 trials): in people with cognitive impairment or dementia, ginkgo results were inconsistent; three of the four most recent trials found no difference from placebo. Nicolai 2013 Cochrane (14 trials) found no clinically significant walking-distance gain in intermittent claudication. The EMA lists ginkgo leaf under well-established use, while NICE advises against herbal products for dementia.

GRADE certainty: Low — rated by Healicus using the GRADE method

Questions people ask

Does Ginkgo biloba work?

Birks & Grimley Evans 2009 Cochrane Database Syst Rev (36 trials): in people with cognitive impairment or dementia, ginkgo results were inconsistent; three of the four most recent trials found no difference from placebo. Nicolai 2013 Cochrane (14 trials) found no clinically significant walking-distance gain in intermittent claudication. The EMA lists ginkgo leaf under well-established use, while NICE advises against herbal products for dementia. Certainty of the evidence: Low, rated by Healicus using the GRADE method.

How is Ginkgo biloba taken?

EGb 761 standardised extract 120–240 mg/day, in one or two divided doses. Timing: Morning, or split morning + evening. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.

Are there interactions or cautions?

Anti-platelet effect; usually stopped at least 2 weeks before surgery. Caution with warfarin, DOACs, antiplatelets, SSRIs, and NSAIDs. Avoid in pregnancy. Seizure threshold concerns at very high doses; avoid in epilepsy. Documented drug and supplement interactions can be looked up in the free interaction reference.

What is the evidence based on?

Sources: Birks & Grimley Evans, Cochrane Database Syst Rev 2009, ginkgo biloba for cognitive impairment and dementia; EMA HMPC monograph, Ginkgo biloba L., folium (Well-Established Use + Traditional Use); Nicolai et al., Cochrane Database Syst Rev 2013, ginkgo biloba for intermittent claudication; NICE guideline (2018): Dementia: assessment, management and support for people living with dementia and their carers (NG97).

One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.